Andriy Yaroshenko
United States
Mr. Daniel Bradbury is a Co-Founder and serves as Executive Chairman at Sensulin. Mr. Daniel Bradbury is the Founder and serves as Managing Member at Biobrit. Dan currently serves on the University of California San Diego's Rady School of Management's Advisory Council and the University of Miami's Innovation Corporate Advisory Council. He serves as Board Member at Biocon. He also serves as President and Board Member at Troia Therapeutics. He served as Co-Chief Executive Officer and Chairman at DiaVacs. He served as Chairman at Freedom Meditech. He serves as an Advisor at Investor Growth Capital. He has served as a director of Geron since September 2012. He also served as a Board Member at Microdermis. He also served as a member of the boards of directors of Liquid Grids, Illumina, Inc., a manufacturer of life-science tools and integrated systems for the analysis of genetic variation and biological function; Corcept Therapeutics, a company focused on the discovery and development of drugs that regulate the effects of cortisol and BioMed Realty, a real estate investment trust focused on providing real estate to the life science industry, as well as being a member of the board of trustees of the Keck Graduate Institute. He also served on the University of California San Diego, Rady School of Management's Advisory Council, the University of Miami's Innovation Corporate Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders, from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin's President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, a pharmaceutical company, holding a number of sales and marketing positions. He also serves as a director at Biomed Realty Trust. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. He served as Chairman at Thesan Pharmaceuticals. He served as Board Member at Nuvation Bio.
Individual/Angel